secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2023-10-26T23:59:59+00:00
Accession:  0001013762-23-006952
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics amends Toray license; royalty cut to 7.5% of net sales, supply deal for FDA path
--------------------------------------------------------------------------------

- Royalty rate reduced from 15% to 7.5% of net sales (or less) for 10-year term; 50% reduction after patent expiry.
- New supply agreement: Toray will manufacture intermediates for FDA-approval cartridges through Oct 2025 or FDA clearance.
- Bluejay obtains right to sublicense Toray IP to Sanyoseiko for manufacturing Symphony device and cartridges for clinical trials.
- Technology transfer from Toray to Sanyoseiko for cartridge manufacturing, enabling commercial scale production.
- Prior upfront license fee of $240,000 already paid; post-commercial minimum annual royalty of $100,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000101376223006952/0001013762-23-006952-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000101376223006952/ea187299-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001013762-23-006952

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer